Kallyope appoints Jeff Goater as CEO in leadership shake-up

By Public Technologies
  • Kallyope, now operating as TriGemX Bio, named Jeff Goater chief executive as it relaunched to focus on migraine drug elismetrep.
  • Goater joined from The Column Group, where he remains a venture partner; he previously led Surface Oncology and served as CFO of Voyager Therapeutics.
  • Aninda Katragadda was appointed chief financial officer; she previously held the same role at Atavistik Bio.
  • Katragadda previously held senior finance roles at Akouos, Surface Oncology, Foghorn Therapeutics, Voyager Therapeutics, The Medicines Company, Vertex, and PwC.
  • TCGX Managing Partner Cariad Chester joined the board following a $94 million financing backing Phase 3 trials of elismetrep.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kallyope Inc. published the original content used to generate this news brief on October 01, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk